Apixaban no better than standard care after TAVR
Following a successful TAVR* procedure, taking apixaban was not superior to standard antithrombotic therapy for the composite primary outcome, regardless of whether patients originally have an indication for oral anticoagulant (OAC), according to the ATLANTIS** trial.
